Targeting RET-rearranged non-small-cell lung cancer: future prospects

• Published in: Lung cancer (Auckland) 2019-03, Vol.10, p.27-36
• Main Authors: Bronte, Giuseppe, Ulivi, Paola, Verlicchi, Alberto, Cravero, Paola, Delmonte, Angelo, Crinò, Lucio
• Format: Article
• Language: English
• Subjects: Alectinib; Antineoplastic agents; Cabozantinib; Cancer therapies; Cancer treatment; Chemotherapy; Clinical trials; Development and progression; Endothelial growth factors; gene rearrangement; Genes; Kinases; Lenvatinib; Lung cancer; Medical research; Motor vehicle drivers; multi-kinase inhibitors; Mutation; Nintedanib; Non-small cell lung cancer; Non-small cell lung carcinoma; Ponatinib; Regorafenib; RET; Review; Sorafenib; Sunitinib; Thyroid cancer; Toxicity; Tumors; Tyrosine kinase inhibitors; Vandetanib; Vascular endothelial growth factor
• ISSN: 1179-2728; 1179-2728
• DOI: 10.2147/LCTT.S192830

Non-small-cell lung cancer (NSCLC) patients with mutated or rearranged oncogene drivers can be treated with upfront selective inhibitors achieving higher response rates and longer survival than chemotherapy. The RET gene can undergo chromosomal rearrangements in 1%-2% of all NSCLC patients, involving various upstream fusion partners such as KIF5B, CCDC6, NCOA4, and TRIM33. Many multikinase inhibitors are active against rearranged RET. Cabozantinib, vandetanib, sunitinib, lenvatinib, and nintedanib achieved tumor responses in about 30% of these patients in retrospective studies. Prospective phase II trials investigated the activity and toxicity of cabozantinib, vandetanib, sorafenib, and lenvatinib, and did not reach significantly higher response rates. VEGFR and EGFR inhibition represented the main ways of developing off-target toxicity. An intrinsic resistance emerged according to the type of RET fusion partners, as KIF5B-RET fusion is the most resistant. Also acquired mutations in rearranged RET oncogene developed as resistance to these multikinase inhibitors. Interestingly, RET fusions have been found as a resistance mechanism to EGFR-TKIs in EGFR-mutant NSCLC patients. The combination of EGFR and RET inhibition can overcome this resistance. The limitations in terms of activity and tolerability of the various multikinase inhibitors prompted the investigation of new highly selective RET inhibitors, such as RXDX-105, BLU-667, and LOXO-292. Some data emerged about intracranial antitumor activity of BLU-667 and LOXO-292. If these novel drugs will achieve high activity in RET rearranged NSCLC, also these oncogene-addicted tumors can undergo a significant survival improvement.